Dr. Yong Chu obtained his Ph.D. from Sichuan University in 2001. He worked as postdoctor in Fudan University and Geogia State University in 2002 and 2008, respectively, and served as PI in Basilea Pharmaceutica (China) Ltd, a wholly own subsidiary of Basilea Pharmaceutica AG of Switzerland for two years. Thereafter, Dr. Chu joined the faculty of Fudan University in 2006 and became an associate professor in 2014. He has published over 20 academic articles in English, and was authorized for six items of China invention patent.
Medicinal chemistry; Therapeutic agents; Imaging tracer, GSK-3β, α-synuclein
Education
Oct. 2001, Ph.D. Department of Medicinal Chemistry, West China Medical Center of Sichuan University.
Aug. 1998, M.S. Department of Colored Metal Metallurgy, Institute of Precious Metal, Kunming.
Aug. 1995, B.S. Department of Chemistry, China West Normal University.
Professional Experiences
Nov.2015-Jan. 2017 Drug examiner, Center For Drug Evaluation (CDE), CFDA
Jan. 2008-Feb. 2009 Post-doctoral research associate with Professor Binghe Wang, Department of Chemistry, Georgia State University, USA
Mar. 2006-present Assistant Professor, Associate Professor, Department of Medicinal Chemistry, School of Pharmacy, Fudan University
Aug. 2004-Feb. 2006 PI, Basilea Pharmaceutica (China) Ltd
June 2002-July.2004 Post-doctoral research associate with Professor Fener Chen, Department of Chemistry, Fudan University
Teaching Activities
Undergraduate: Organic chemistry
Graduate: Advanced Organic Chemistry Lab, Progress in Medicinal Chemistry, Modern organic synthesis technology
Grants & Projects
1. Early diagnosis to Parkinson's Disease, Key projects of the Ministry of science and technology (2016YFC1306500), 2016-2020
2. Design, optimization and mechanism study of novel non-ATP-competitive GSK-3β inhibitors to treat diabetes，PI, National Natural Science Foundation (81373275), 2014.01-2017.12
3. PET imaging on Early diagnosis to Parkinson's Disease, Sub-PI, Key projects of basic research in Shanghai Municipal Science and Technology Commission (13JC1401103), 2013.7-2016.6
4. Optimization to Novel non-ATP competitive GSK-3β inhibitors, PI, Shanghai Institute of Medicine key state laboratories open projects (SIMM1302KF-11), 2013.03-2014.04
5. Screening of non-ATP competitive GSK-3β inhibitors, PI, Natural Science Foundation of Shanghai (10ZR1401800), 2010.4-2013.3
6. Screening of sphingomyelin synthase inhibitors, PI, Fudan university，2009.10－2010.10
7. Developing novel non-ATP-competitive GSK-3β inhibitors to treat diabetes，PI, Research Fund for the Doctoral Program of Higher Education of China (20070246089), 2008.01-2010.12
Selected Publications（latest 5 yrs，<20 papers）
1. Yang Gao, Peng Zhang, Anfeng Cui, De-Yong Ye, Meng Xiang*, Yong Chu*. Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).Bioorg Med Chem. 2018 Sep 22. pii: S0968-0896(18)30697-7. doi: 10.1016/j.bmc.2018.09.027.
2. Yang Gao, Deyong Ye*, Wei-cheng Zhou*, Yong Chu*, The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer [J]. European Journal of Medicinal Chemistry, 2017, 135, 370-381
3. Zhang, Peng，Ye, Deyong，Chu, Yong*，An efficient one-pot procedure for the synthesis of 1,5-benzothiazepinones catalyzed by tetrabutylammonium fluoride (TBAF)，Tetrahedron Letters；2016，57(2016) 3743-3745
4. Peng Zhang#, Shufen Li#, Yang Gao, Wenbo Lu, Ke Huang, De-Yong Ye, Xi Li*,Yong Chu*, Novel Benzothiazinones (BTOs) as Allosteric Modulator or Substrate Competitive Inhibitor of Glycogen Synthase Kinase 3β (GSK-3β) with Cellular Activity of Promoting Glucose Uptake. Bioorg. Med. Chem. Lett., 2014, 24(24): 5639-5643
5. Peng Zhang, Hai-Rong Hu, Shi-Hui Bian, Zhao-Hui Huang, Yong Chu* and De-Yong Ye*，Design, Synthesis and Biological Evaluation of Benzothiazepinones (BTZs) as Novel Non-ATP Competitive Inhibitors of Glycogen Synthase Kinase-3β (GSK-3β). Eur. J.Med. Chem. 2013, 61:95-103
6. Yong Chu，Danzhu Wang，Ke Wang，Zhiren (Luis) Liu，Brent Weston，Binghe Wang*，Fluorescent conjugate of sLex-selective bisboronic acid for imaging application. Bioorg. Med. Chem. Lett. , 2013, 23: 6307-6309
7. Wenbo Lu，Peng Zhang，Ke Huang，Yong Chu*，De-Yong Ye *, Design, synthesis and biological evaluation of benzothiazinones as novel non-ATP competitive inhibitors of glycogen synthesis kinase 3β (GSK-3β). Chinese Journal of Medicinal Chemistry,2013, 23(6):444-452
Patents
Authorized
1. ZL201310360516.2 Yong Chu, Wenbo Lu, Peng Zhang, Deyong Ye GSK-3β抑制剂或其盐及其药物用途
2. ZL201210019998.0 Yong Chu, Peng Zhang, Deyong Ye, Hairong Hu 2,3-二氢苯并氮杂?类化合物或其盐及其药物用途。
3. ZL201010144779.6 Yong Chu Zhaohui Huang, Deyong Ye, Hairong Hu 3,4-二氢苯并[f][1,4] 噻氮杂类化合物或其盐及其药物用途。
4. ZL200910174456.9 Yong Chu, Zhaohui Huang, Hairong Hu, Deyong Ye 2,3-二氢[1,5]苯并噻氮杂?类化合物或其盐在制备GSK-3β抑制剂中的用途。
5. ZL 200310108912.2 Yong Chu, Fener Chen 2,3-二甲氧基-5-甲基-1,4苯醌的制备方法
6. ZL 200410017832 Fener Chen, Yong Chu 一种多取代苯醌的制备方法
Applying
1. CN2018101533478 Yong Chu, Yanfei Chen, Jian Wang, Deyong Ye, Jiang Bian, Peng Zhang 一种能强结合α-突触核蛋白聚集体的化合物、其制备方法及其用途
2. CN20171001126022017 1 6 Yong Chu, Yang Gao, Deyong Ye 苯并噻嗪酮类化合物及其制备方法和药物用途
3. WO2013013130，DAI, Chaofeng; (US).，CAZARES, Lisa, H.; (US).，WANG, Binghe; (US).，WANG, Lifang; (US).，CHU, Yong; (CN).，WANG, Siming, L.; (US).，TROYER, Dean, A.; (US).，DRAKE, Richard, R.; (US).，CHEN, Weixuan; (US)，Cellular Recognition Conjugates And Methods Of Use For The Histological Analysis Of Cancer Tissue Using MALDI-MS Imaging.
4. CN201410476100.1 Deyong Ye, Yali Li, Lu Zhou, Xiaodong Deng, Yong Chu, Yanping Dong 4-氨酰基苯氧乙酰胺类化合物及其在医药上的用途
5. CN2014104019334.2 Deyong Ye, Yali Li, Lu Zhou, Penghui Wang, Yong Chu, Haojun Gong, Qi Huang, Yan Chen, Zhikuan Zhang 2-烷氧基苯甲酰芳胺类化合物及其药物用途
6. CN 2017100428357 Deyong Ye, Xiangyu Qi, Yali Li, Mingguang Mo, Lu Zhou, Yong Chu, Penghui Wang 2-苄氧苯基噁唑并吡啶类化合物及其药物用途
